Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07425899
PHASE1
A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants
Sponsor: AbbVie
View on ClinicalTrials.gov
Summary
This is a Phase 1 study to investigate safety and pharmacokinetics of ABBV-722 and Upadacitinib following multiple oral doses in healthy adult participants.
Official title: A Phase 1 Study to Evaluate the Pharmacokinetic Interaction and Safety of ABBV-722 and Upadacitinib Following Multiple Oral Doses in Healthy Adult Subjects
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2026-02-26
Completion Date
2026-08
Last Updated
2026-03-31
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
ABBV-722
Oral
DRUG
Upadacitinib
Oral
Locations (1)
Acpru /Id# 279285
Grayslake, Illinois, United States